Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions.

Willmore-Payne C, Holden JA, Zhou H, Gupta D, Hirschowitz S, Wittwer CT, Layfield LJ.

Arch Pathol Lab Med. 2006 May;130(5):691-8.

PMID:
16683887
[PubMed - indexed for MEDLINE]
2.

Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.

Baumhoer D, Smida J, Specht K, Bink K, Quintanilla-Martinez L, Rosemann M, Siggelkow H, Nathrath WB, Atkinson MJ, Bielack S, Jundt G, Nathrath M.

Hum Pathol. 2011 Jun;42(6):859-66. doi: 10.1016/j.humpath.2010.09.016. Epub 2011 Feb 2.

PMID:
21292304
[PubMed - indexed for MEDLINE]
3.

Quantitative assessment of HER2/neu expression by real-time PCR and fluorescent in situ hybridization analysis in low-grade osteosarcoma.

Lee WI, Bacchni P, Bertoni F, Maeng YH, Park YK.

Oncol Rep. 2004 Jul;12(1):125-8.

PMID:
15201972
[PubMed - indexed for MEDLINE]
4.

Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas.

Maitra A, Wanzer D, Weinberg AG, Ashfaq R.

Cancer. 2001 Aug 1;92(3):677-83.

PMID:
11505415
[PubMed - indexed for MEDLINE]
5.

Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification.

Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE.

J Pediatr Hematol Oncol. 2003 Jan;25(1):27-32.

PMID:
12544770
[PubMed - indexed for MEDLINE]
6.

Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.

Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L.

Clin Cancer Res. 2002 Mar;8(3):788-93.

PMID:
11895910
[PubMed - indexed for MEDLINE]
Free Article
7.
8.

Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue.

Fellenberg J, Krauthoff A, Pollandt K, Delling G, Parsch D.

Lab Invest. 2004 Jan;84(1):113-21.

PMID:
14631380
[PubMed - indexed for MEDLINE]
Free Article
9.

HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization.

Moelans CB, de Weger RA, van Blokland MT, Ezendam C, Elshof S, Tilanus MG, van Diest PJ.

Cell Oncol. 2009;31(1):1-10.

PMID:
19096145
[PubMed - indexed for MEDLINE]
10.

HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study.

Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS.

Pediatr Dev Pathol. 2005 Sep-Oct;8(5):525-32. Epub 2005 Oct 5.

PMID:
16211448
[PubMed - indexed for MEDLINE]
11.

Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas.

Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PM, Taminiau AH, Nooij M, Egeler RM, Hogendoorn PC.

Eur J Cancer. 2004 May;40(7):963-70.

PMID:
15093570
[PubMed - indexed for MEDLINE]
12.

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.

Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ.

Hum Pathol. 1997 Jul;28(7):827-33.

PMID:
9224752
[PubMed - indexed for MEDLINE]
13.

HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis.

Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Aisner S, Hameed M.

Cancer Invest. 2004;22(1):16-24.

PMID:
15069760
[PubMed - indexed for MEDLINE]
14.

An alternative and reliable real-time quantitative PCR method to determine HER2/neu amplification in breast cancer.

Egervari K, Toth J, Nemes Z, Szollosi Z.

Appl Immunohistochem Mol Morphol. 2009 May;17(3):247-54. doi: 10.1097/PAI.0b013e3181907a60.

PMID:
19098680
[PubMed - indexed for MEDLINE]
15.

Isolation of osteosarcoma-associated amplified DNA sequences using representational difference analysis.

Simons A, Janssen IM, Suijkerbuijk RF, Veth RP, Pruszczynski M, Hulsbergen-van de Kaa CA, du Manoir S, Geurts van Kessel A.

Genes Chromosomes Cancer. 1997 Oct;20(2):196-200.

PMID:
9331570
[PubMed - indexed for MEDLINE]
16.

Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors.

Flint AF, U'Ren L, Legare ME, Withrow SJ, Dernell W, Hanneman WH.

Vet Pathol. 2004 May;41(3):291-6.

PMID:
15133183
[PubMed - indexed for MEDLINE]
Free Article
17.

Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis.

Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA, Eigenbrot C, Yee H, Steiner G, Greco MA.

Hum Pathol. 2007 Aug;38(8):1184-91. Epub 2007 May 23.

PMID:
17509661
[PubMed - indexed for MEDLINE]
18.

Determination of HER-2/Neu status in hepatocellular carcinoma cases.

Bacaksiz A, Sahin FI, Bilezikci B, Yilmaz Z.

Genet Test. 2008 Jun;12(2):211-4. doi: 10.1089/gte.2007.0095.

PMID:
18452393
[PubMed - indexed for MEDLINE]
19.

Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.

Persons DL, Borelli KA, Hsu PH.

Mod Pathol. 1997 Jul;10(7):720-7.

PMID:
9237184
[PubMed - indexed for MEDLINE]
20.

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.

Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, Fisher HA, Rifkin MD, Muraca PJ.

Cancer. 1997 Jun 1;79(11):2162-70.

PMID:
9179063
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk